ReviewInternational journal of hematology2010
Classification and diagnosis of myeloproliferative neoplasms according to the 2008 World Health Organization criteria.
Review in International journal of hematology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 101 citations in OpenAlex.
- Multicenter analysis of the use of transjugular intrahepatic portosystemic shunt for management of MPN-associated portal hypertension.American journal of hematology · 2017Trial
- Clinical and Molecular Diagnostic Evaluation of Systemic Mastocytosis in the South-Eastern Hungarian Population Between 2001-2013--A Single Centre Experience.Pathology oncology research : POR · 2016Trial
- A multinational, open-label, phase 2 study of ruxolitinib in Asian patients with myelofibrosis: Japanese subset analysis.International journal of hematology · 2015Trial
- Demographics, clinical features, and comorbidities of high-altitude polycythaemia: a multicentre, retrospective, observational study.Journal of global health · 2026Observational
- Disabled, invisible and dismissed-The lived experience of fatigue in people with myeloproliferative neoplasms.Cancer reports (Hoboken, N.J.) · 2023Article
- Progress in elucidation of molecular pathophysiology of myeloproliferative neoplasms and its application to therapeutic decisions.International journal of hematology · 2020Review
- Reduced expression but not deficiency of GFI1 causes a fatal myeloproliferative disease in mice.Leukemia · 2019Article
- Physical Activity as a Nonpharmacological Symptom Management Approach in Myeloproliferative Neoplasms: Recommendations for Future Research.Integrative cancer therapies · 2017Review
- A Genetic Screen Reveals an Unexpected Role for Yorkie Signaling in JAK/STAT-Dependent Hematopoietic Malignancies inG3 (Bethesda, Md.) · 2017Article
- Overexpression of lncRNA NEAT1 mitigates multidrug resistance by inhibiting ABCG2 in leukemia.Oncology letters · 2016Article
- The Role of IL-33-Dependent Inflammation in the Tumor Microenvironment.Frontiers in immunology · 2016Review
- The JAK2 V617F Mutation in Plasma Cell Neoplasms with Co-existing Erythrocytosis.Journal of clinical and diagnostic research : JCDR · 2015Article
- Anesthetic management of a patient with polycythemia vera undergoing emergency repair of a type-A aortic dissection and concomitant coronary artery bypass grafting: a case report.Korean journal of anesthesiology · 2015Article
- IL-33 signaling contributes to the pathogenesis of myeloproliferative neoplasms.The Journal of clinical investigation · 2015Article
- [The impact of autophagy on proliferation of HEL cells and hematopoietic cells of polycythemia vera patients with JAK2 V617F mutation].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2015Article
- Bone cement augmentation procedures for spinal pathologic fractures by multiple myeloma.Journal of Korean medical science · 2015Article
- Does HOXA9 Gene Expression in Egyptian Chronic Myelogenous Leukemia Patients Affect Disease Progression? A Retrospective Cohort Study.Turkish journal of haematology : official journal of Turkish Society of Haematology · 2013Article
- Multiple Myeloma and Epidural Spinal Cord Compression : Case Presentation and a Spine Surgeon's Perspective.Journal of Korean Neurosurgical Society · 2013Article
- Platelet derived growth factor receptor-beta (PDGFRβ) expression is limited to activated stromal cells in the bone marrow and shows a strong correlation with the grade of myelofibrosis.Virchows Archiv : an international journal of pathology · 2013Article
- Could hypoxia increase the prevalence of thrombotic complications in polycythemia vera?Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The myeloproliferative neoplasms (MPNs) were first recognized by William Dameshek in 1951. The classic MPNs were polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (PMF) and chronic myelogenous leukemia. They were originally grouped together based on their shared phenotype of myeloproliferation. Since then, important discoveries have been made, identifying a central role of protein tyrosine kinases in the pathogenesis of these disorders. As such, the 2008 WHO diagnostic classification for myeloproliferative neoplasms has incorporated molecular markers with histologic, clinical and laboratory information into the diagnostic algorithms for the MPNs. Important changes include (1) the change of nomenclature of myeloproliferative disorder to myeloproliferative neoplasm emphasizing the clonal nature of these disorders; (2) the classification of mast cell disease as an MPN; (3) the reorganization of the eosinophilic disorders into a molecularly defined category of PDGFRA, PDGFRB and FGFR1-associated myeloid and lymphoid neoplasms with eosinophilia and chronic eosinophilic leukemia, not otherwise specified; and (4) refinement of the diagnostic criteria for PV, ET and PMF incorporating recently described molecular markers, JAK2V617F, JAK2 exon 12 mutations and MPL mutations. This review focuses upon the important changes of the 2008 WHO diagnostic criteria for MPNs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.